Astrazeneca Share News (AZN)

Astrazeneca Information

Buy AZN Shares
Add AZN to Watchlist
Add AZN to Alert

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 12,416.00

Bid: 12,408.00

Ask: 12,410.00

Change: -12.00 (-0.10%)

Spread: 2.00 (0.016%)

Open: 12,474.00

High: 12,480.00

Low: 12,350.00

Prev. Close: 12,428.00

Last checked at -

Tuesday broker round-up

Tue, 25th May 2021 13:07

(Sharecast News) - Travis Perkins: Deutsche Bank resumes coverage with a recommendation to hold and a target price of 1,707p.

TUI: Berenberg reiterates sell with a target price of 175p.

Barclays: Berenberg reiterates buy with a target price of 220p.

Kainos: Canaccord reiterates hold with a target price of 1,515p.

Travis Perkins: Canaccord reiterates buy with a target price of 1,730p.

Smiths Group: Citigroup reiterates buy with a target price of 1,900p.

AstraZeneca: Deutsche Bank reiterates buy with a target price of 10,200p.

GSK: Deutsche Bank reiterates sell with a target price of 1,200p.

Big Yellow: Liberum reiterates hold with a target price of 1,150p.

Hill & Smith: Numis upgrades to buy with a target price of 1,800p.

Atalaya Mining: Peel Hunt reiterates buy with a target price of 500p.

More News

Today 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Today 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Today 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Latest Share Chat

Astrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up

Login to your account

Quickpicks are a member only feature

Login to your account